Angela C. Brown-pettigrew

Array ( [id] => 9149027 [patent_doc_number] => 20130303550 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-14 [patent_title] => 'CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 13/885127 [patent_app_country] => US [patent_app_date] => 2011-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27283 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13885127 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9149076 [patent_doc_number] => 20130303599 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-14 [patent_title] => 'IRE1ALPHA ENDONUCLEASE SPECIFIC INHIBITOR WITH CYTOTOXIC ACTIVITY' [patent_app_type] => utility [patent_app_number] => 13/883502 [patent_app_country] => US [patent_app_date] => 2011-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 3490 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13883502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10515920 [patent_doc_number] => 09242958 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-01-26 [patent_title] => 'Substituted pyridazine carboxamide compounds as kinase inhibitor compounds' [patent_app_type] => utility [patent_app_number] => 13/877812 [patent_app_country] => US [patent_app_date] => 2011-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 14652 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13877812 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10528179 [patent_doc_number] => 09254292 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-02-09 [patent_title] => 'Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases' [patent_app_type] => utility [patent_app_number] => 13/876931 [patent_app_country] => US [patent_app_date] => 2011-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40358 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13876931 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11191463 [patent_doc_number] => 09422262 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-08-23 [patent_title] => 'Compounds and methods for treating diseases mediated by protease activated receptors' [patent_app_type] => utility [patent_app_number] => 13/825574 [patent_app_country] => US [patent_app_date] => 2011-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 10953 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13825574 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8892337 [patent_doc_number] => 20130165521 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-27 [patent_title] => 'TREATMENT OF FUNGAL INFECTIONS' [patent_app_type] => utility [patent_app_number] => 13/822072 [patent_app_country] => US [patent_app_date] => 2011-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5158 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13822072 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8884891 [patent_doc_number] => 20130158075 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-20 [patent_title] => 'HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS' [patent_app_type] => utility [patent_app_number] => 13/820240 [patent_app_country] => US [patent_app_date] => 2011-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 126179 [patent_no_of_claims] => 66 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13820240 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8990430 [patent_doc_number] => 20130217711 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-22 [patent_title] => 'Use of a Receptor-Type Kinase Modulator for Treating Polycystic Kidney Disease' [patent_app_type] => utility [patent_app_number] => 13/818844 [patent_app_country] => US [patent_app_date] => 2011-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18170 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13818844 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8904840 [patent_doc_number] => 20130172343 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-07-04 [patent_title] => 'Derivatives of 1H-isoindol-3-amine, 1H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as Beta-secretase Inhibitors' [patent_app_type] => utility [patent_app_number] => 13/814232 [patent_app_country] => US [patent_app_date] => 2011-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42185 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13814232 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9135697 [patent_doc_number] => 20130296412 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-07 [patent_title] => 'Artemisinin-Like Derivatives with Cytotoxic and Anti-Angiogenic Properties' [patent_app_type] => utility [patent_app_number] => 13/813741 [patent_app_country] => US [patent_app_date] => 2011-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 7362 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13813741 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10641387 [patent_doc_number] => 09358237 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-06-07 [patent_title] => 'Noribogaine compositions' [patent_app_type] => utility [patent_app_number] => 13/383405 [patent_app_country] => US [patent_app_date] => 2011-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5346 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 5 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13383405 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8815286 [patent_doc_number] => 20130116331 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-09 [patent_title] => 'MEDICAL GEL' [patent_app_type] => utility [patent_app_number] => 13/638080 [patent_app_country] => US [patent_app_date] => 2011-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4081 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13638080 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9299855 [patent_doc_number] => 08648083 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-02-11 [patent_title] => 'Method of treating diabetic hyperlipidemia or hyperlipidemia with carbamoyloxy arylalkanoyl arylpiperazine compounds' [patent_app_type] => utility [patent_app_number] => 13/805098 [patent_app_country] => US [patent_app_date] => 2011-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 6 [patent_no_of_words] => 7703 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 221 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13805098 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7501734 [patent_doc_number] => 20110263597 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-10-27 [patent_title] => 'SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY' [patent_app_type] => utility [patent_app_number] => 13/177833 [patent_app_country] => US [patent_app_date] => 2011-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26176 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0263/20110263597.pdf [firstpage_image] =>[orig_patent_app_number] => 13177833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8768101 [patent_doc_number] => 20130096138 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-04-18 [patent_title] => 'NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT' [patent_app_type] => utility [patent_app_number] => 13/805334 [patent_app_country] => US [patent_app_date] => 2011-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11918 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13805334 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7720898 [patent_doc_number] => 20120010233 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-01-12 [patent_title] => 'METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE' [patent_app_type] => utility [patent_app_number] => 13/154923 [patent_app_country] => US [patent_app_date] => 2011-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 92 [patent_figures_cnt] => 92 [patent_no_of_words] => 46768 [patent_no_of_claims] => 79 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0010/20120010233.pdf [firstpage_image] =>[orig_patent_app_number] => 13154923 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8854216 [patent_doc_number] => 20130143891 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-06 [patent_title] => 'Methods for Treating Methotrexate-Resistant Disorders with 10-Propargyl-10-Deazaaminopterin' [patent_app_type] => utility [patent_app_number] => 13/702650 [patent_app_country] => US [patent_app_date] => 2011-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 10303 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13702650 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8842066 [patent_doc_number] => 20130137694 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-30 [patent_title] => 'NOVEL MODULATORS OF NRF2 AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/704449 [patent_app_country] => US [patent_app_date] => 2011-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 5406 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13704449 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9503588 [patent_doc_number] => 08741903 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-06-03 [patent_title] => 'Organic compound for use in the treatment of hepatocellular cancer (HCC)' [patent_app_type] => utility [patent_app_number] => 13/641668 [patent_app_country] => US [patent_app_date] => 2011-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 3579 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13641668 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9004484 [patent_doc_number] => 20130225609 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-29 [patent_title] => 'COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR-ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 13/639629 [patent_app_country] => US [patent_app_date] => 2011-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 31190 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13639629 [rel_patent_id] =>[rel_patent_doc_number] =>)